Skip to main content

Table 1 This is a comprehensive list of all the studies that included the Nuss procedure

From: Systematic review of surgical treatment techniques for adult and pediatric patients with pectus excavatum

Reference

n

Study type

Follow-up (years)

Age, mean (range), years

Operation duration, min

Analgesia duration, epidural/ IV, days

Mean blood loss, mL

Mean LOS, days

Outcome, >good/ excellent, %

Non-displacement complication/ self-resolving, %

Requiring reoperation, %

Bar displacement, %

Number of bars removed, %

Symptoms

Lung function

Cardiac function

Esteves [[35]] a

19

R

 

22.6 (20–27)

96.5

3/--

 

6.1

 

0/--

  

21

   

Teh [[36]]

19

R

2.4 (.3-5.9)

19.5 (17–42)

126

3/--

 

5.8

 

42/31

10.5

10.5

32

   

Cheng [[37]] b

96

P

1.8 (0.4 - 3.0)

24.5 (18–42)

80 c

 

<10

7.2

92/73

3/1

2

2

7

   

Hebra [[38]]

30

R

 

23 (18–32)

 

3/--

 

6

86/50

20/4

 

6.7

    

Aronson [[39]]

35

  

23 (18–47)

65 c

(4–5)/--

 

7 c

 

34/--

 

14.3

40

   

Schalamon [[40]] b

43

P

1.9 (0.5 - 5)

22 (18–39)

70

  

9.3

--/91

23/--

0

2.3

35

 

Same

 

Kim [[32]]

12

R

3.4

27 (20–52)

127.3

  

10

64/--

58/--

42

8.3

    

Coln [[41]]

8

R

1.8

(19–32)

92

2.8/<5

 

4

 

100/50

0

25

50

Better

 

Better

Zganjer [42]

128

R

3.6

13.8 (8–21)

 

--/4

35

10

95/73d

41/20

4.7

4.7

42

Better

 

Better

Esteves [35]a

26

R

 

15.3 (5.0-19)

90.3

3/--

 

5.07

 

4/--

  

12

   

Nuri [43]

12

R

3.6 (0.3 - 7)

9 (4.0-21)

      

0

33.3

    

Densmore [44]

117

R

4

12.9 (8.0-18)

118

--/3.8

<10

5.8

 

21/--

16

12

100

   

Mao [45]

115

R

 

7.9 (2.7-18)

59.5

--/5.1

 

8.5

98/90

20/6

1.7

2.6

32

   

Felts [46]

25

 

2.2

13.8 (5.0-18)

 

3/--

 

7

96/--

20/--

4

4

52

 

Better

 

Lam [25]

19

R

 

15.4 (13–18)

72.1

3.7/--

 

4.5

        

Sigalet [47]

26

P

>2

13.2

   

5

  

11.5

11.5

 

Better

Better

Same

Kubiak [48]

15

  

15.9 (10.7-18.1)

     

33/20

6.7

13.3

  

Better

Better

Kelly [24]a,b

284

P

0.2

13.6 (8.0-21)

    

97/90

98/47

 

2.5

    

Coln [49]a

123

R

<2

13 (5.0-18)

 

--/2.9

 

3.1

 

11/--

 

0.8

 

Better

 

Better

Aronson [39]

141

  

13 (5.0-17)

65c

  

7c

 

24/--

0.7

12.8

55

   

Kim [32]

39

R

3.4

8.9 (1.5-19)

60.7

  

5.9

83/--

25/--

7.7

5.1

    

Bohosiewicz [50]

66

R

 

11.8 (1.0-19)

    

--/85

15/--

1.5

 

36

   

Watanabe [51]

53

R

 

9 (4.0-18)

76

--/4.3

4

8.9

 

26/2

3.8

7.5

    

Ohno [33]

23

R

 

7.6 (3.0-19)

143.5

 

16.5

7.9

--/78

13/--

 

8.7

    

Inge [30]

43

R

1.4 (0.6 - 2.8)

11 (4–19)

70

0/--

 

2.4

90/

14/--

4.7

4.7

    

Fonkalsrud [34]

68

R

 

12 (5.0-19)

75

3/5

90

6.5

 

13/--

10.2

8.8

26

   

Molik [27]

35

R

 

9.5 (5.0-20)

198

3/3.8

 

4.8

 

37/--

22.9

17.1

    

Miller [29]

80

R

 

9.4 (<21)

53

 

20

3.7

95/--

45/8

5

5

20

Better

  

Engum [52]

20

R

1.2 (0.2-1.6)

8.2 (5–15)

   

4.9

 

40/35

15

20

    

Nuss [21]

42

R

4.6 (1–9.2)

(<15)

  

15

4.3

87/73d

24/7

4.8

4.8

    
  1. The table is divided horizontally with bold & plain text to differentiate between pediatric and adult patients. Within each subgroup studies are organized in reverse chronological order from top to bottom based on publication date.
  2. a= >3% patients reported to have Marfans.
  3. b = >20% of patients reported to have scoliosis.
  4. c = Median (not included in weighted averages).
  5. d = specified as long-term outcomes.
  6. P/R = Prospective/Retrospective Cohort Study.